Reuters logo
BRIEF-Biomerieux and Astute Medical to develop and market Nephrocheck test
January 22, 2015 / 6:22 AM / 3 years ago

BRIEF-Biomerieux and Astute Medical to develop and market Nephrocheck test

Jan 22 (Reuters) - Biomerieux SA :

* Biomerieux and Astute Medical sign a global agreement to develop and market Nephrocheck test for Vidas, an assay to assess the risk of developing acute kidney injury

* Test detects the presence of two biomarkers: TIMP-2 (Tissue Inhibitor Metalloproteinases-2) and IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7) Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below